Results 261 to 270 of about 371,009 (363)
The features and risk factors of thrombotic thrombocytopenic purpura in systemic lupus erythematosus. [PDF]
Orphanet J Rare DisMa H, He Y, Li S, Yang Y, Huo L, Li T.
europepmc +1 more source
Rheumatology &Autoimmunity, EarlyView.Peripheral blood mononuclear cells were isolated from 12 systemic lupus erythematosus (SLE) patients and 12 healthy controls. The number and function of peripheral blood CD141+ dendritic cells (DCs) were compared between patients and controls. Moreover, the tolerogenic properties of CD141+ and CD1c+ DCs were compared in SLE patients.
Xiaodong Qin +4 more
wiley +1 more source
Rural-urban disparities in hospitalisation for myocardial infarction in systemic lupus erythematosus in the USA. [PDF]
Lupus Sci MedSingh JA, Chandrupatla S.
europepmc +1 more source
Case of Lupus erythematosus treated by Zinc Ionization with satisfactory Results
, 1909 E. G. Graham Little
openalex +1 more source
Rheumatology &Autoimmunity, EarlyView.This review seeks to provide a thorough synthesis of the existing literature on the role of thrombopoietin receptor agonists in the treatment of primary and secondary immune thrombocytopenia, with particular emphasis on the compound Hetrombopag. Abstract Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by a platelet count below
Jiaqi Hu +8 more
wiley +1 more source
IL-10 in Systemic Lupus Erythematosus: Balancing Immunoregulation and Autoimmunity. [PDF]
Int J Mol SciRichter P +5 more
europepmc +1 more source
Rheumatology &Autoimmunity, EarlyView.Recent multi‐omics studies have demonstrated that belimumab specifically targets naïve B cells and a subset of memory B cells. This observation is consistent with belimumab's established efficacy and safety profile. Abstract Belimumab is an antibody targeting the cytokine B‐cell activating factor (BAFF), which is crucial for B cell differentiation, and
Keishi Fujio +5 more
wiley +1 more source